canceldeath
Registry update — unassessed

Sirolimus in Older Adults- Randomized Trial Assessing the Improvement in Phenotypic/Functional Biomarkers of Aging

Trial registry update: RECRUITING. No results reported in the supplied registry record.

RCTRoutine significance
Reporter brief

What this changes

The finding has not established an approved change to our evidence assessment.

Source date: Jun 25, 2026 · Discovered: Sep 18, 2026 · Assessed: — · Historical research backfill

What it does not prove

  • No efficacy or safety data are presented, making this a protocol or preliminary description rather than a completed trial report
  • The absence of results precludes any conclusion about whether rapamycin actually affects aging biomarkers or clinical outcomes in older adults
  • The stated hypothesis about mTOR inhibition slowing aging is based on animal studies and theory, not demonstrated clinical evidence from this trial

Extracted from supplied source material; model confidence is not a measured probability of correctness.

Design
Rct
Sample size
—
Duration
—
Population
Older adults
Primary outcome
Reduction in biomarkers of aging processes
Effect size
—
Significance
Not reported
Journal
NOT_REPORTED
Published
Jun 25, 2026

Recorded source passages

Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.

The proposed study addresses critical gaps in our understanding of the safety and efficacy of sirolimus in delaying aging processes and is based on findings in animal studies and incidental clinical observations. The investigators will overcome potential biases with a randomized control trial.
Specifically, the investigators aim to investigate whether sirolimus can reduce the occurrence or increase in biomarkers of aging processes.

Source versions

Version 1: Unassessed

Version 1: Superseded

Assessment history

One thread per scientific event, no matter how many outlets covered it.

Sign in to join the discussion.

No comments yet

Be the first to weigh in on this evidence.